Effect of Aqueous Cinnamon Extract on the Postprandial Glycaemia Levels in Type 2 Diabetes Mellitus

Sponsor
Egas Moniz - Cooperativa de Ensino Superior, CRL (Other)
Overall Status
Completed
CT.gov ID
NCT05145673
Collaborator
(none)
36
2
9.4

Study Details

Study Description

Brief Summary

The type 2 diabetes mellitus is a chronic disease and it is a highly prevalent globally. Cinnamon is a spicy used on the traditional cuisine, which have as been associated with beneficial effects on postprandial blood glucose levels (BGL). The aim of the present study was to investigate the effect of cinnamon tea (6g C. burmannii/100mL) on postprandial glycaemia in type 2 diabetic adults.

Following ethical committee approval, thirty-six subjects were selected and randomly allocated in 2 groups (n=18): cinnamon group, which was administrated OGTT (oral glucose tolerance test) followed by cinnamon tea; control group, which was administrated only OGTT. At baseline, anthropometric data, medical condition and pharmacological therapy were collected. A 24-hour dietary recall was taken preceding each intervention. Food Processor SQL (version 10.5.9) program was used to analyze the food nutritional composition. Chemical analysis was performed for total phenols determinations (adapted from Prabha et al) and antioxidant activity for FRAP and for DPPH tests (adapted from K. Thaipong et al.) Statistical analysis was performed using SPSS Statistics program. Data are mean±SEM.

Condition or Disease Intervention/Treatment Phase
  • Other: Placebo (OGTT)
  • Other: Cinnamon (OGTT plus aqueous cinnamon extract)
N/A

Detailed Description

Type 2 diabetes mellitus (DM2) subjects aged between 35-77 years were recruited into this study through nutrition appointment, Holon Pharmacy from Lisbon and Portalegre, Portugal. After the approval of the Ethics Committee, 36 individuals, were selected and invited to participate in this study. After eligibility criteria applied, a randomized controlled clinical trial, blind to participants, was conducted to 36 DM2 subjects. Participants were randomly assigned to intervention (n=18) or control group (n=18). The first participant of the study was randomly allocated to intervention or control group and the following participants were systematically allocated in each group. The anonymity and the confidentiality of the participants data collected were guaranteed through a code attributed to each participant. The control group was given a glucose solution to oral glucose tolerance test (OGTT) and the intervention group was given a glucose solution to OGTT followed by a cinnamon aqueous extract. The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.

Aqueous cinnamon extract was prepared by Cinnamomum burmannii bark (from Sucrame Company, Portugal) with Indonesia origin. Sticks of cinnamon (60 g) were soaked into 1000 mL of water. After 24 h at room temperature, cinnamon solution was heated for 30 min at 100°C and then filtered at room temperature. After the cinnamon tea preparation a 100 mL individual dose was distributed to each participant. For chemical analysis, a hydromethanolic extract (50 : 50) was performed with aqueous cinnamon extract previously obtained.

Anthropometric paraments and pharmacological therapy data were collected at the beginning of the study. At day before the intervention, a 24-hour food recall questionnaire was employed to participants of the study and carefully instructed by an investigator to complete the food record. The Food Processor SQL (10.14.2. version) programme was applied to analysed the nutritional composition of meals, such as, total energy intake (Kcal), proteins (g), lipids (g), carbohydrates (g), dietary fibre (g) and soluble fibre (g). It were also estimated the glycemic index and glycemic load of food intake.

Based on the blood glucose values, the blood glucose incremental area under the curve (AUCi) of each participant was defined using the GraphPad Prism program (version 5.0). Maximum concentrations (Cmax) and variations of maximum concentrations (ΔCmax) were determined by comparing with its respective baseline glycemia levels values.

The total phenolic concentration in the C. burmanni extract was determined according to Folin-Ciocalteu method employing gallic acid as standard. For the determination of antioxidant activity two methods were performed: FRAP and DPPH, adapted by Thaipong et al. The FRAP method for determination of ferric reducing effect was based on the reduction, at low pH, employing a colourless ferric complex (Fe3+) to a blue-coloured ferrous complex (Fe2+) by electron-donating antioxidants action in 2,4,6-tri(2-pyridyl)-s-triazine (TPTZ) presence.

Study Design

Study Type:
Interventional
Actual Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of Aqueous Cinnamon Extract on the Postprandial Glycaemia Levels in Type 2 Diabetes Mellitus: a Randomized Controlled Trial
Actual Study Start Date :
Jan 19, 2016
Actual Primary Completion Date :
Oct 3, 2016
Actual Study Completion Date :
Oct 31, 2016

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo (OGTT)

The control group was given an glucose solution to oral glucose tolerance test (OGTT) .

Other: Placebo (OGTT)
The control group was given an glucose solution to oral glucose tolerance test (OGTT) The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.

Experimental: Cinnamon (OGTT plus aqueous cinnamon extract)

The Experimental group was given an glucose solution to oral glucose tolerance test (OGTT) followed by aqueous cinnamon extract.

Other: Cinnamon (OGTT plus aqueous cinnamon extract)
The intervention group was given an glucose solution to OGTT followed by a cinnamon aqueous extract. The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.

Outcome Measures

Primary Outcome Measures

  1. Blood glucose levels at beginning [At beginning (before intervention)]

    Mean values of blood glucose levels from both control and experimental groups

  2. Blood glucose levels at 30 minutes [At 30 minutes after intervention]

    Mean values of blood glucose levels from both control and experimental groups

  3. Blood glucose levels at 60 minutes [At 60 minutes after intervention]

    Mean values of blood glucose levels from both control and experimental groups

  4. Blood glucose levels at 90 minutes [At 90 minutes after intervention]

    Mean values of blood glucose levels from both control and experimental groups

  5. Blood glucose levels at 120 minutes [At 120 minutes after intervention]

    Mean values of blood glucose levels from both control and experimental groups

  6. Incremental area under the curve of blood glucose [At 120 minutes after intervention]

    Based on the blood glucose values, the blood glucose incremental area under the curve (AUCi) of each participant was defined using the GraphPad Prism program (version 5.0)

  7. Variation of blood glucose maximum concentration [At 60 minutes after intervention]

    Mean values of glucose maximum concentration variation

Secondary Outcome Measures

  1. Anthropometric parameters - body weight [At baseline]

    Mean values of body weight (in kilogram - Kg)

  2. Anthropometric parameters - height [At baseline]

    Mean values of Height (in centimeters - cm)

  3. Anthropometric parameters - waist circumference [At baseline]

    Mean values of waist circumference (in centimeters - cm)

  4. Anthropometric parameters - body mass index [At baseline]

    Mean values of body mass index (Kg/m2), calculated as weight (Kg) divided by height (m2) squared (Kg/m2)

  5. Anthropometric parameters - Skeletal muscle mass [At baseline]

    Mean values of Skeletal muscle mass (in kilogram - Kg)

  6. Anthropometric parameters - visceral fat [At baseline]

    Mean values of visceral fat (cm3)

  7. Pharmacological therapy [At baseline]

    Percentage of antidiabetic orals (biguanide, sulfonylurea, alpha-glucosidase inhibitor, dipeptidyl peptidase 4 inhibitors

  8. Total protein intake [At baseline]

    Means values of total protein intake (in grams - g) obtained through The Food Processor SQL software

  9. Total lipid intake [At baseline]

    Means values of total lipid intake (in grams - g) obtained through The Food Processor SQL software

  10. Total carbohydrate intake [At baseline]

    Means values of total carbohydrate intake (in grams - g) obtained through The Food Processor SQL software

  11. Total energy intake [At baseline]

    Means values of total energy intake (in kilocalorie - Kcal) obtained through The Food Processor SQL software

  12. Total polyphenols content [At baseline]

    Mean values of total polyphenols content of cinnamon extract (mg/L equivalent of gallic acid)

  13. Antioxidant activity [At baseline]

    Mean values of antioxidant activity of cinnamon extract by FRAP and DPPH assays (micromol Trolox/L)

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 77 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • subjects aged 18 years or older

  • subjects with DM2 diagnostic and men or non-pregnant women.

Exclusion Criteria:
  • insulin-treated subjects

  • history of gastrointestinal symptoms/diseases

  • allergy to cinnamon

  • fasting less than 8 hours

  • cinnamon intake at day before the intervention

  • intense exercise until 2 hours before the intervention

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Egas Moniz - Cooperativa de Ensino Superior, CRL

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Egas Moniz - Cooperativa de Ensino Superior, CRL
ClinicalTrials.gov Identifier:
NCT05145673
Other Study ID Numbers:
  • 525cinnamon
First Posted:
Dec 6, 2021
Last Update Posted:
Dec 6, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 6, 2021